Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frankel, A.
Right arrow Articles by Mills, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frankel, A.
Right arrow Articles by Mills, G. B.

Clinical Cancer Research, Vol 2, Issue 8 1307-1313, Copyright © 1996 by American Association for Cancer Research


ARTICLES

Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells

A Frankel and GB Mills
Oncology Research Toronto Hospital, Toronto, Ontario, Canada M5G 2C4

Growth factors have been demonstrated to regulate the proliferation and viability of a number of cell lineages. Because most drugs used in chemotherapy kill cells through programmed cell death, by the process of apoptosis, we determined whether growth factors, specifically epidermal growth factor (EGF) and lysophosphatidic acid (LPA), which we have demonstrated recently to be a potent growth factor for ovarian cancer cells, would alter the ability of cis-diamminedichloroplatinum (cis-DDP), the most effective chemotherapeutic agent for ovarian cancer, to kill the HEY ovarian cancer cell line. We demonstrate that both EGF and LPA decrease the ability of cis-DDP to kill HEY ovarian cancer cells as assessed by colony-forming cell activity and dye reduction. Morphological changes, DNA release, and electron microscopy suggested that LPA and EGF protect ovarian cancer cells from programmed cell death induced by cis-DDP. Because LPA is present in high levels in ascitic fluid from ovarian cancer patients, and the EGF receptor is expressed by tumor cells from a significant portion of patients where it correlates with prognosis, growth factor modulation of cis-DDP-induced apoptosis may play a role in the poor prognosis associated with ovarian cancer.


This article has been cited by other articles:


Home page
Stem CellsHome page
J. Chen, A. R. Baydoun, R. Xu, L. Deng, X. Liu, W. Zhu, L. Shi, X. Cong, S. Hu, and X. Chen
Lysophosphatidic Acid Protects Mesenchymal Stem Cells Against Hypoxia and Serum Deprivation-Induced Apoptosis
Stem Cells, January 1, 2008; 26(1): 135 - 145.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
M. M. Murph, J. Hurst-Kennedy, V. Newton, D. N. Brindley, and H. Radhakrishna
Lysophosphatidic Acid Decreases the Nuclear Localization and Cellular Abundance of the p53 Tumor Suppressor in A549 Lung Carcinoma Cells
Mol. Cancer Res., November 1, 2007; 5(11): 1201 - 1211.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Klemm, S. Zimmermann, C. Peschel, T. W. Mak, and J. Ruland
Bcl10 and Malt1 control lysophosphatidic acid-induced NF-{kappa}B activation and cytokine production
PNAS, January 2, 2007; 104(1): 134 - 138.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Pilquil, J. Dewald, A. Cherney, I. Gorshkova, G. Tigyi, D. English, V. Natarajan, and D. N. Brindley
Lipid Phosphate Phosphatase-1 Regulates Lysophosphatidate-induced Fibroblast Migration by Controlling Phospholipase D2-dependent Phosphatidate Generation
J. Biol. Chem., December 15, 2006; 281(50): 38418 - 38429.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
F.-q. Wang, Y. Smicun, N. Calluzzo, and D. A. Fishman
Inhibition of Matrilysin Expression by Antisense or RNA Interference Decreases Lysophosphatidic Acid-Induced Epithelial Ovarian Cancer Invasion
Mol. Cancer Res., November 1, 2006; 4(11): 831 - 841.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Macleod, P. Mullen, J. Sewell, G. Rabiasz, S. Lawrie, E. Miller, J. F. Smyth, and S. P. Langdon
Altered ErbB Receptor Signaling and Gene Expression in Cisplatin-Resistant Ovarian Cancer
Cancer Res., August 1, 2005; 65(15): 6789 - 6800.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Hu, N. Haney, D. Kropp, A. F. Kabore, J. B. Johnston, and S. B. Gibson
Lysophosphatidic Acid (LPA) Protects Primary Chronic Lymphocytic Leukemia Cells from Apoptosis through LPA Receptor Activation of the Anti-apoptotic Protein AKT/PKB
J. Biol. Chem., March 11, 2005; 280(10): 9498 - 9508.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C.-H. Chou, L.-H. Wei, M.-L. Kuo, Y.-J. Huang, K.-P. Lai, C.-A. Chen, and C.-Y. Hsieh
Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-{kappa}B pathway by lysophosphatidic acid, an ovarian cancer-activating factor
Carcinogenesis, January 1, 2005; 26(1): 45 - 52.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Fang, S. Yu, R. C. Bast, S. Liu, H.-J. Xu, S.-X. Hu, R. LaPushin, F. X. Claret, B. B. Aggarwal, Y. Lu, et al.
Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells
J. Biol. Chem., March 5, 2004; 279(10): 9653 - 9661.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J. Lu, Y.-j. Xiao, L. M. Baudhuin, G. Hong, and Y. Xu
Role of ether-linked lysophosphatidic acids in ovarian cancer cells
J. Lipid Res., March 1, 2002; 43(3): 463 - 476.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. Tigyi
Selective Ligands for Lysophosphatidic Acid Receptor Subtypes: Gaining Control over the Endothelial Differentiation Gene Family
Mol. Pharmacol., December 1, 2001; 60(6): 1161 - 1164.
[Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. J. A. Contos, I. Ishii, and J. Chun
Lysophosphatidic Acid Receptors
Mol. Pharmacol., April 13, 2001; 58(6): 1188 - 1196.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Imai, T. Furui, T. Tamaya, and G. B. Mills
A Gonadotropin-Releasing Hormone-Responsive Phosphatase Hydrolyses Lysophosphatidic Acid within the Plasma Membrane of Ovarian Cancer Cells
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3370 - 3375.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
A. M. Eder, T. Sasagawa, M. Mao, J. Aoki, and G. B. Mills
Constitutive and Lysophosphatidic Acid (LPA)-induced LPA Production: Role of Phospholipase D and Phospholipase A2
Clin. Cancer Res., June 1, 2000; 6(6): 2482 - 2491.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
T. Furui, R. LaPushin, M. Mao, H. Khan, S. R. Watt, M.-A. V. Watt, Y. Lu, X. Fang, S. Tsutsui, Z. H. Siddik, et al.
Overexpression of Edg-2/vzg-1 Induces Apoptosis and Anoikisin Ovarian Cancer Cells in a Lysophosphatidic Acid-independent Manner
Clin. Cancer Res., December 1, 1999; 5(12): 4308 - 4318.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Xu, L. M. Love, I. Singh, Q.-X. Zhang, J. Dewald, D.-A. Wang, D. J. Fischer, G. Tigyi, L. G. Berthiaume, D. W. Waggoner, et al.
Lipid Phosphate Phosphatase-1 and Ca2+ Control Lysophosphatidate Signaling through EDG-2 Receptors
J. Biol. Chem., September 1, 2000; 275(36): 27520 - 27530.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.